Cancer Immunotherapy Manufacturers, Suppliers & Companies (Medical Specialties)
-
Manufacturerbased in Santa Barbara, CALIFORNIA (USA)
Owl Biomedical, Inc. was founded in 2011 to expand the use of its exclusive cell sorting MEMS technology for cell therapy, cancer diagnostics and basic research. Operating in Santa Barbara, California, Owl Biomedical was purchased in 2013 by ...
-
Research institutebased in Bangkok, THAILAND
The Regeneration Center provides comprehensive and scientifically backed stem cell treatments for numerous conditions and degenerative diseases. Through years of research and clinical applications of modern cellular therapeutics our internationally ...
-
Software vendorbased in Oslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
NEC - Neoantigens Enable Personalized Cancer Immunotherapy Technology
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in ...
CONTACT SUPPLIER -
Technologybased in Oxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
Vaccines and T cell Immunotherapies Technology
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been ...
CONTACT SUPPLIER -
Manufacturerbased in Utrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Lava - Model 051 - Pipeline
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept ...
CONTACT SUPPLIER -
Manufacturerbased in Tuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Developing Adoptive Cell Therapies Services
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
CONTACT SUPPLIER -
Manufacturerbased in Oxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
ImmunoBody - Cancer Vaccines
ImmunoBody vaccines are designed to generate potent T cell responses capable of a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of an antibody, but the parts of the antibody that would normally bind to the target ...
CONTACT SUPPLIER -
Manufacturerbased in Monmouth Junction, NEW JERSEY (USA)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal ...
-
Manufacturerbased in London, UNITED KINGDOM
Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases. Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx ...
HEMO-CAR-T Immunotherapy
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal ...
CONTACT SUPPLIER -
Manufacturerbased in Menlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
CONTACT SUPPLIER -
Manufacturerbased in Nantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
Tedopi - Neo-Epitope-Based Vaccine
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T ...
CONTACT SUPPLIER -
Manufacturerbased in Vienna, AUSTRIA
Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology ...
Cancer Immunotherapy Technology
Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle ...
CONTACT SUPPLIER -
Technologybased in Vancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks - Model EFECT - Customize & Optimize Immune Response Cell
using precise antibody Fc modifications that tailor the antibody-mediated immune response. Get the optimal response. Tailor immune system response for a desired therapeutic effect using the Effector Function Enhancement and Control ...
CONTACT SUPPLIER -
Technologybased in Wien, AUSTRIA
BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and ...
BlueSky - Interferon-inducing Viral Vectors (delNS)
The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral ...
CONTACT SUPPLIER -
Technologybased in Pennington, NEW JERSEY (USA)
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform. Through our proprietary technology, we are working to deliver safe and effective cancer treatments that can provide ...
OncoSec - Model TAVO - Tavokinogene Telseplasmid + Electroporation (EP) Gene Delivery Technology
We are developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. We have built a deep clinical pipeline utilizing our primary technology, TAVO™ (tavokinogene telseplasmid) ...
CONTACT SUPPLIER -
Manufacturerbased in Olathe, KANSAS (USA)
TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved ...
Immunotherapy for the Treatment of Kidney Cancer and Targets Stage 4 Renal Cell Carcinoma
TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell ...
CONTACT SUPPLIER -
Manufacturerbased in Palo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc - Model IO-202 - (Anti-LILRB4) Mechanisms of Action in Hematologic Malignancies Program
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
CONTACT SUPPLIER -
Manufacturerbased in West Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
BriaCell - Model Bria-OTS - Off-the-Shelf Personalized Immunotherapy Cell Lines
We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, ...
CONTACT SUPPLIER -
Manufacturerbased in Dartmouth, NOVA SCOTIA (CANADA)
We Advance Novel Immunotherapies for Hard-to-Treat Cancers. IMV Inc. is a clinical-stage pharmaceutical company that has the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer. We have built ...
IMV - Model Maveropepimut-S (DPX-Survivac) - Generating Cancer-Targeted Killer T Cells
Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in ...
CONTACT SUPPLIER -
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
Alphageneron Pharmaceuticals is a clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer cells (NK) cell and antibody-based therapies to treat cancer. Our seasoned team of biopharmaceutical executives, ...
Model ENKASTIM - Autologous mHsp70 Targeted NK Cell Therapy
An autologous mHsp70 targeted NK Cell Therapy that activates NK cells to target and kill cells expressing mHsp70. The therapy begins with selecting patients whom have high mHsp70 expression with our Companion Diagnostic AP-CDx (described below), ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you